| Cell biology |
| The animal cell |
Components of a typical animal cell:
- Nucleolus
- Nucleus
- Ribosome (little dots)
- Vesicle
- Rough endoplasmic reticulum
- Golgi apparatus (or "Golgi body")
- Cytoskeleton
- Smooth endoplasmic reticulum
- Mitochondrion
- Vacuole
- Cytosol (fluid that contains organelles, comprising the cytoplasm)
- Lysosome
- Centrosome
- Cell membrane
|
A lysosome[help 1] is a membrane-bound organelle found in most animal cells. They are spherical vesicles which contain hydrolytic enzymes that can break down virtually all kinds of biomolecules. Simply stated, a lysosome is a type of vesicle with specific composition, of both its membrane proteins, and proteins of its lumen. The lumen's pH (4.5 - 5.0)[1] is optimal for the enzymes involved in hydrolysis, analogous to the activity of the stomach. Besides degradation of polymers, the lysosome is involved in various cell processes, including secretion, plasma membrane repair, cell signalling and energy metabolism.[2]
The lysosomes also act as the waste disposal system of the cell by digesting unwanted materials in the cytoplasm, both from outside of the cell and obsolete components inside the cell. Material from the outside of the cell is taken-up through endocytosis, while material from the inside of the cell is digested through autophagy. Their sizes can be very different—the biggest ones can be more than 10 times bigger than the smallest ones.[3] They were discovered and named by Belgian biologist Christian de Duve, who eventually received the Nobel Prize in Physiology or Medicine in 1974.
Lysosomes are known to contain more than 50 different enzymes. Enzymes of the lysosomes are synthesised in the rough endoplasmic reticulum. The enzymes are imported from the Golgi apparatus in small vesicles, which fuse with larger acidic vesicles. Enzymes destined for a lysosome are specifically tagged with the molecule mannose 6-phosphate, so that they are properly sorted into acidified vesicles.[citation needed]
Synthesis of lysosomal enzymes is controlled by nuclear genes. Mutations in the genes for these enzymes are responsible for more than 30 different human genetic diseases, which are collectively known as lysosomal storage diseases. These diseases result from an accumulation of specific substrates, due to the inability to break them down. These genetic defects are related to several neurodegenerative disorders, cancer, cardiovascular diseases, and ageing-related diseases.[4][5]
Contents
- 1 Discovery
- 2 Function and structure
- 3 Formation
- 4 Pathogen entry
- 5 Disease
- 6 Lysosomotropism
- 7 Controversy in botany
- 8 See also
- 9 Notes
- 10 References
- 11 External links
Discovery
TEM views of various vesicular compartments. Lysosomes are denoted by "Ly". They are dyed dark due to their acidity; in the center of the top image, a Golgi Apparatus can be seen, distal from the cell membrane relative to the lysosomes.
Christian de Duve, then chairman of the Laboratory of Physiological Chemistry at the Catholic University of Louvain in Belgium, had been studying the mechanism of action of a pancreatic hormone insulin in liver cells. By 1949, he and his team had focused on the enzyme called glucose 6-phosphatase, which is the first crucial enzyme in sugar metabolism and the target of insulin. They already suspected that this enzyme played a key role in regulating blood sugar levels. However, even after a series of experiments, they failed to purify and isolate the enzyme from the cellular extracts. Therefore, they tried a more arduous procedure of cell fractionation, by which cellular components are separated based on their sizes using centrifugation.
They succeeded in detecting the enzyme activity from the microsomal fraction. This was the crucial step in the serendipitous discovery of lysosomes. To estimate this enzyme activity, they used that of standardised enzyme acid phosphatase, and found that the activity was only 10% of the expected value. One day, the enzyme activity of purified cell fractions which had been refrigerated for five days was measured. Surprisingly, the enzyme activity was increased to normal of that of the fresh sample. The result was the same no matter how many times they repeated the estimation, and led to the conclusion that a membrane-like barrier limited the accessibility of the enzyme to its substrate, and that the enzymes were able to diffuse after a few days (and react with their substrate). They described this membrane-like barrier as a "saclike structure surrounded by a membrane and containing acid phosphatase."[6]
It became clear that this enzyme from the cell fraction came from a membranous fractions, which were definitely cell organelles, and in 1955 De Duve named them "lysosomes" to reflect their digestive properties.[7] The same year, Alex B. Novikoff from the University of Vermont visited de Duve´s laboratory, and successfully obtained the first electron micrographs of the new organelle. Using a staining method for acid phosphatase, de Duve and Novikoff confirmed the location of the hydrolytic enzymes of lysosomes using light and electron microscopic studies.[8][9] de Duve won the Nobel Prize in Physiology or Medicine in 1974 for this discovery.
Originally, De Duve had termed the organelles the "suicide bags" or "suicide sacs" of the cells, for their hypothesized role in apoptosis.[10] However, it has since been concluded that they only play a minor role in cell death.[11]
Function and structure
Lysosomes contain a variety of enzymes in order to be able to break down the variety of biomolecules engulfed by the cell, including peptides, nucleic acids, carbohydrates, and lipids. The enzymes responsible for this hydrolysis require an acidic environment for optimal activity.
In addition to being able to break down polymers, lysosomes are capable of fusing with other organelles & digesting large structures or cellular debris; through cooperation with phagosomes, they are able to conduct autophagy, clearing out damaged structures. Similarly, they are able to break-down virus particles or bacteria in phagocytosis of macrophages.
The size of lysosomes varies from 0.1–1.2 μm.[12] At pH 4.5 - 5, the interior of the lysosomes is acidic compared to the slightly basic cytosol (pH 7.2). The lysosomal membrane protects the cytosol, and therefore the rest of the cell, from the degradative enzymes within the lysosome. The cell is additionally protected from any lysosomal acid hydrolases that drain into the cytosol, as these enzymes are pH-sensitive and do not function well or at all in the alkaline environment of the cytosol. This ensures that cytosolic molecules and organelles are not destroyed in case there is leakage of the hydrolytic enzymes from the lysosome.
The lysosome maintains its pH differential by pumping in protons (H+ ions) from the cytosol across the membrane via proton pumps and chloride ion channels. Vacuolar H+-ATPases are responsible for transport of protons, while the counter transport of chloride ions is performed by ClC-7 Cl−/H+ antiporter. In this way a steady acidic environment is maintained.[13][14]
It sources its versatile capacity for degradation by import of enzymes with specificity for different substrates; cathepsins are the major class of hydrolytic enzymes, while lysosomal alpha-glucosidase (GAA) is responsible for carbohydrates, and ACP2 is necessary to release phosphate groups of phospholipids.
Formation
The Lysosome is shown in purple, as an endpoint in Endocytotic sorting. AP2 is necessary for vesicle formation, whereas the Mannose-6-receptor is necessary for sorting Hydrolase into the Lysosome's lumen.
Many components of animal cells are recycled by transferring them inside or embedded in sections of membrane. For instance, in endocytosis (more specifically, macropinocytosis), a portion of the cell’s plasma membrane pinches off to form a vesicle that will eventually fuse with an organelle within the cell. Without active replenishment, the plasma membrane would continuously decrease in size. It is thought that lysosomes participate in this dynamic membrane exchange system and are formed by a gradual maturation process from endosomes.[15][16]
The production of lysosomal proteins suggests one method of lysosome sustainment. Lysosomal protein genes are transcribed in the nucleus. mRNA transcripts exit the nucleus into the cytosol, where they are translated by ribosomes. The nascent peptide chains are translocated into the rough endoplasmic reticulum, where they are modified. Upon exiting the endoplasmic reticulum and entering the Golgi apparatus via vesicular transport, a specific lysosomal tag, mannose 6-phosphate, is added to the peptides. The presence of these tags allow for binding to mannose 6-phosphate receptors in the Golgi apparatus, a phenomenon that is crucial for proper packaging into vesicles destined for the lysosomal system.[17]
Upon leaving the Golgi apparatus, the lysosomal enzyme-filled vesicle fuses with a late endosome, a relatively acidic organelle with an approximate pH of 5.5. This acidic environment causes dissociation of the lysosomal enzymes from the mannose 6-phosphate receptors. The enzymes are packed into vesicles for further transport to established lysosomes.[17] The late endosome itself can eventually grow into a mature lysosome, as evidenced by the transport of endosomal membrane components from the lysosomes back to the endosomes.[15]
Pathogen entry
Cholera gaining entry into a cell via endocytosis.
As the endpoint of endocytosis, the lysosome also acts as a safeguard in preventing pathogens from being able to reach the cytoplasm before being degraded. Pathogens often hijack endocytotic pathways such as pinocytosis in order to gain entry into the cell. The lysosome prevents easy entry into the cell by hydrolyzing the biomolecules of pathogens necessary for their replication strategies; reduced Lysosomal activity results in an increase in viral infectivity, including HIV.[18] In addition, AB5 toxins such as cholera hijack the endosomal pathway while evading lysosomal degradation.[18]
Disease
Lysosomes are responsible for a group of genetically inherited disorders called lysosomal storage diseases (LSD). They are a type of inborn errors of metabolism caused by malfunction of one of the enzymes. The rate of incidence is estimated to be 1 in 5,000 live births, and the true figure expected to be higher as many cases are likely to be undiagnosed or misdiagnosed. The primary cause is deficiency of an acidic hydrolase (a hydrolase which functions best in acidic environments). Other conditions are due to defects in lysosomal membrane proteins that fail to transport the enzyme, non-enzymatic soluble lysosomal proteins. The initial effect of such disorders is accumulation of specific macromolecules or monomeric compounds inside the endosomal–autophagic–lysosomal system.[4] This results in abnormal signaling pathways, calcium homeostasis, lipid biosynthesis and degradation and intracellular trafficking, ultimately leading to pathogenetic disorders. The organs most affected are brain, viscera, bone and cartilage.[19][20]
There is no direct medical treatment to cure LSDs.[21] The most common LSD is Gaucher's disease, which is due to deficiency of the enzyme glucocerebrosidase. Consequently, the enzyme substrate, the fatty acid glucosylceramide accumulates, particularly in white blood cells, which in turn affects spleen, liver, kidneys, lungs, brain and bone marrow. The disease is characterized by bruises, fatigue, anaemia, low blood platelets, osteoporosis, and enlargement of the liver and spleen.[22][23]
Metachromatic leukodystrophy is another lysosomal storage disease that also affects sphingolipid metabolism.
Lysosomotropism
Weak bases with lipophilic properties accumulate in acidic intracellular compartments like lysosomes. While the plasma and lysosomal membranes are permeable for neutral and uncharged species of weak bases, the charged protonated species of weak bases do not permeate biomembranes and accumulate within lysosomes. The concentration within lysosomes may reach levels 100 to 1000 fold higher than extracellular concentrations. This phenomenon is called "lysosomotropism"[24] or "acid trapping". The amount of accumulation of lysosomotropic compounds may be estimated using a cell-based mathematical model.[25]
A significant part of the clinically approved drugs are lipophilic weak bases with lysosomotropic properties. This explains a number of pharmacological properties of these drugs, such as high tissue-to-blood concentration gradients or long tissue elimination half-lifes; these properties have been found for drugs such as haloperidol,[26] levomepromazine,[27] and amantadine.[28] However, high tissue concentrations and long elimination half-lives are explained also by lipophilicity and absorption of drugs to fatty tissue structures. Important lysosomal enzymes, such as acid sphingomyelinase, may be inhibited by lysosomally accumulated drugs.[29][30] Such compounds are termed FIASMAs (functional inhibitor of acid sphingomyelinase)[31] and include for example fluoxetine, sertraline, or amitriptyline.
Ambroxol is a lysosomotropic drug of clinical use to treat conditions of productive cough for its mucolytic action. Ambroxol triggers the exocytosis of lysosomes via neutralization of lysosomal pH and calcium release from acidic calcium stores.[32] Presumably for this reason, Ambroxol was also found to improve cellular function in some disease of lysosomal origin such as Parkinson's or lysosomal storage disease.[33][34]
Controversy in botany
By scientific convention, the term lysosome is applied to those vesicular organelles only in animals, and vacuoles to plants, fungi and algae. Discoveries in plant cells since the 1970s started to challenge this definition. Plant vacuoles are found to be much more diverse in structure and function than previously thought.[35][36] Some vacuoles contain their own hydrolytic enzymes and perform the classic lysosomal activity, which is autophagy.[37][38][39] These vacuoles are therefore seen as fulfilling the role of the animal lysosome. Based on de Duve's description that “only when considered as part of a system involved directly or indirectly in intracellular digestion does the term lysosome describe a physiological unit”, some botanists strongly argued that these vacuoles are lysosomes.[40] However, this is not universally accepted as the vacuoles are strictly not similar to lysosomes, such as in their specific enzymes and lack of phagocytic functions.[41] Vacuoles do not have catabolic activity and do not undergo exocytosis as lysosomes do.[42]
See also
- Peroxisome
- Cathelicidin
- Antimicrobial peptides
- Innate immune system
Notes
- ^ The word lysosome (, ) is New Latin that uses the combining forms lyso- (referring to lysis and derived from the Latin lysis, meaning "to loosen", via Ancient Greek λύσις [lúsis]), and -some, from soma, "body", yielding "body that lyses" or "lytic body". The adjectival form is lysosomal. The forms *lyosome and *lyosomal are much rarer; they use the lyo- form of the prefix but are often treated by readers and editors as mere unthinking replications of typos, which has no doubt been true as often as not.
References
- ^ Mindell, Joseph A. “Lysosomal Acidification Mechanisms.” Annual Review of Physiology 74 (2012): 69–86. doi:10.1146/annurev-physiol-012110-142317.
- ^ Settembre C, Fraldi A, Medina DL, Ballabio A (May 2013). "Signals from the lysosome: a control centre for cellular clearance and energy metabolism". Nature Reviews Molecular Cell Biology 14 (5): 283–96. doi:10.1038/nrm3565. PMID 23609508.
- ^ Lüllmznn-Rauch R (2005). "History and Morphology of Lysosome". In Zaftig P. Lysosomes (Online-Ausg. 1 ed.). Georgetown, Tex.: Landes Bioscience/Eurekah.com. pp. 1–16. ISBN 978-0-387-28957-1.
- ^ a b Platt FM, Boland B, van der Spoel AC (Nov 2012). "The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction". The Journal of Cell Biology 199 (5): 723–34. doi:10.1083/jcb.201208152. PMC 3514785. PMID 23185029.
- ^ He LQ, Lu JH, Yue ZY (May 2013). "Autophagy in ageing and ageing-associated diseases". Acta Pharmacologica Sinica 34 (5): 605–11. doi:10.1038/aps.2012.188. PMC 3647216. PMID 23416930.
- ^ Susana Castro-Obregon (2010). "The Discovery of Lysosomes and Autophagy". Nature Education 3 (9): 49.
- ^ de Duve C (Sep 2005). "The lysosome turns fifty". Nature Cell Biology 7 (9): 847–9. doi:10.1038/ncb0905-847. PMID 16136179.
- ^ Novikoff AB, Beaufay H, De Duve C (Jul 1956). "Electron microscopy of lysosomerich fractions from rat liver". The Journal of Biophysical and Biochemical Cytology 2 (4 Suppl): 179–84. doi:10.1083/jcb.2.4.179. PMC 2229688. PMID 13357540.
- ^ Klionsky DJ (Aug 2008). "Autophagy revisited: a conversation with Christian de Duve". Autophagy 4 (6): 740–3. doi:10.4161/auto.6398. PMID 18567941.
- ^ Hayashi, Teru, and others. “Subcellular Particles.” Subcellular Particles., 1959.
- ^ Turk, Boris, and Vito Turk. “Lysosomes as ‘Suicide Bags’ in Cell Death: Myth or Reality?” The Journal of Biological Chemistry 284, no. 33 (August 14, 2009): 21783–87. doi:10.1074/jbc.R109.023820.
- ^ Kuehnel W (2003). Color Atlas of Cytology, Histology, & Microscopic Anatomy (4th ed.). Thieme. p. 34. ISBN 1-58890-175-0.
- ^ Mindell JA (2012). "Lysosomal acidification mechanisms". Annual Review of Physiology 74 (1): 69–86. doi:10.1146/annurev-physiol-012110-142317. PMID 22335796.
- ^ Ishida Y, Nayak S, Mindell JA, Grabe M (Jun 2013). "A model of lysosomal pH regulation". The Journal of General Physiology 141 (6): 705–20. doi:10.1085/jgp.201210930. PMC 3664703. PMID 23712550.
- ^ a b Alberts B, et al. (2002). Molecular biology of the cell (4th ed.). New York: Garland Science. ISBN 0-8153-3218-1.
- ^ Falcone S, Cocucci E, Podini P, Kirchhausen T, Clementi E, Meldolesi J (Nov 2006). "Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events". Journal of Cell Science 119 (Pt 22): 4758–69. doi:10.1242/jcs.03238. PMID 17077125.
- ^ a b Lodish H, et al. (2000). Molecular cell biology (4th ed.). New York: Scientific American Books. ISBN 0-7167-3136-3.
- ^ a b Wei, Bangdong L., Paul W. Denton, Eduardo O’Neill, Tianci Luo, John L. Foster, and J. Victor Garcia. “Inhibition of Lysosome and Proteasome Function Enhances Human Immunodeficiency Virus Type 1 Infection.” Journal of Virology 79, no. 9 (2005): 5705–12.
- ^ Schultz ML, Tecedor L, Chang M, Davidson BL (Aug 2011). "Clarifying lysosomal storage diseases". Trends in Neurosciences 34 (8): 401–10. doi:10.1016/j.tins.2011.05.006. PMC 3153126. PMID 21723623.
- ^ Lieberman AP, Puertollano R, Raben N, Slaugenhaupt S, Walkley SU, Ballabio A (May 2012). "Autophagy in lysosomal storage disorders". Autophagy 8 (5): 719–30. doi:10.4161/auto.19469. PMC 3378416. PMID 22647656.
- ^ Parenti G, Pignata C, Vajro P, Salerno M (Jan 2013). "New strategies for the treatment of lysosomal storage diseases (review)". International Journal of Molecular Medicine 31 (1): 11–20. doi:10.3892/ijmm.2012.1187. PMID 23165354.
- ^ Rosenbloom BE, Weinreb NJ (2013). "Gaucher disease: a comprehensive review". Critical Reviews in Oncogenesis 18 (3): 163–75. doi:10.1615/CritRevOncog.2013006060. PMID 23510062.
- ^ Sidransky E (Oct 2012). "Gaucher disease: insights from a rare Mendelian disorder". Discovery Medicine 14 (77): 273–81. PMID 23114583.
- ^ de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F (Sep 1974). "Commentary. Lysosomotropic agents". Biochemical Pharmacology 23 (18): 2495–531. doi:10.1016/0006-2952(74)90174-9. PMID 4606365.
- ^ Trapp S, Rosania GR, Horobin RW, Kornhuber J (Oct 2008). "Quantitative modeling of selective lysosomal targeting for drug design". European Biophysics Journal 37 (8): 1317–28. doi:10.1007/s00249-008-0338-4. PMC 2711917. PMID 18504571.
- ^ Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl KW, Leblhuber F, Riederer P (Jun 1999). "Persistence of haloperidol in human brain tissue". The American Journal of Psychiatry 156 (6): 885–90. doi:10.1176/ajp.156.6.885. PMID 10360127.
- ^ Kornhuber J, Weigmann H, Röhrich J, Wiltfang J, Bleich S, Meineke I, Zöchling R, Härtter S, Riederer P, Hiemke C (Mar 2006). "Region specific distribution of levomepromazine in the human brain". Journal of Neural Transmission 113 (3): 387–97. doi:10.1007/s00702-005-0331-3. PMID 15997416.
- ^ Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (Jul 1995). "Therapeutic brain concentration of the NMDA receptor antagonist amantadine". Neuropharmacology 34 (7): 713–21. doi:10.1016/0028-3908(95)00056-c. PMID 8532138.
- ^ Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E (Jan 2008). "Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model". Journal of Medicinal Chemistry 51 (2): 219–37. doi:10.1021/jm070524a. PMID 18027916.
- ^ Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P (2011). Riezman H, ed. "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE 6 (8): e23852. doi:10.1371/journal.pone.0023852. PMC 3166082. PMID 21909365.
- ^ Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E (2010). "Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications". Cellular Physiology and Biochemistry 26 (1): 9–20. doi:10.1159/000315101. PMID 20502000.
- ^ Fois, Giorgio; Hobi, Nina; Felder, Edward; Ziegler, Andreas; Miklavc, Pika; Walther, Paul; Radermacher, Peter; Haller, Thomas; Dietl, Paul. "A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca2+ release from acidic Ca2+ stores". Cell Calcium 58 (6): 628–637. doi:10.1016/j.ceca.2015.10.002.
- ^ Albin, Roger L.; Dauer, William T. (2014-05-01). "Magic shotgun for Parkinson’s disease?". Brain 137 (5): 1274–1275. doi:10.1093/brain/awu076. ISSN 0006-8950. PMID 24771397.
- ^ McNeill, Alisdair; Magalhaes, Joana; Shen, Chengguo; Chau, Kai-Yin; Hughes, Derralyn; Mehta, Atul; Foltynie, Tom; Cooper, J. Mark; Abramov, Andrey Y. (2014-05-01). "Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells". Brain 137 (5): 1481–1495. doi:10.1093/brain/awu020. ISSN 0006-8950. PMC 3999713. PMID 24574503.
- ^ Marty F (Apr 1999). "Plant vacuoles". The Plant Cell 11 (4): 587–600. doi:10.2307/3870886. PMC 144210. PMID 10213780.
- ^ Samaj J, Read ND, Volkmann D, Menzel D, Baluska F (Aug 2005). "The endocytic network in plants". Trends in Cell Biology 15 (8): 425–33. doi:10.1016/j.tcb.2005.06.006. PMID 16006126.
- ^ Matile, P (1978). "Biochemistry and Function of Vacuoles". Annual Review of Plant Physiology 29 (1): 193–213. doi:10.1146/annurev.pp.29.060178.001205.
- ^ Moriyasu Y, Ohsumi Y (Aug 1996). "Autophagy in Tobacco Suspension-Cultured Cells in Response to Sucrose Starvation". Plant Physiology 111 (4): 1233–1241. doi:10.1104/pp.111.4.1233. PMC 161001. PMID 12226358.
- ^ Jiao BB, Wang JJ, Zhu XD, Zeng LJ, Li Q, He ZH (Jan 2012). "A novel protein RLS1 with NB-ARM domains is involved in chloroplast degradation during leaf senescence in rice". Molecular Plant 5 (1): 205–17. doi:10.1093/mp/ssr081. PMID 21980143.
- ^ Swanson SJ, Bethke PC, Jones RL (May 1998). "Barley aleurone cells contain two types of vacuoles. Characterization Of lytic organelles by use of fluorescent probes". The Plant Cell 10 (5): 685–98. doi:10.2307/3870657. PMC 144374. PMID 9596630.
- ^ Holtzman E (1989). Lysosomes. New York: Plenum Press. pp. 7, 15. ISBN 978-0306-4-3126-5.
- ^ De DN (2000). Plant Cell Vacuoles: An Introduction. Australia: Csiro Publishing. ISBN 978-0-643-09944-9.
External links
|
Look up lysosome in Wiktionary, the free dictionary. |
- This article incorporates public domain material from the NCBI document "Science Primer".
- 3D structures of proteins associated with lysosome membrane
- Hide and Seek Foundation For Lysosomal Research
- Lysosomal Disease Network, a research consortium funded by the NIH through its NCATS/Rare Diseases Clinical Research Network
- Self-Destructive Behavior in Cells May Hold Key to a Longer Life
- Mutations in the Lysosomal Enzyme–Targeting Pathway and Persistent Stuttering
- Animation showing how lysosomes are made, and their function
|
Structures of the cell / organelles (TH H1.00.01.2-3)
|
|
| Endomembrane system |
- Cell membrane
- Nucleus
- Nucleolus
- Endoplasmic reticulum
- Golgi apparatus
- Parenthesome
- Autophagosome
- Vesicles
- Exosome
- Lysosome
- Endosome
- Phagosome
- Vacuole
- Acrosome
- Cytoplasmic granules
- Melanosome
- Microbody
- Glyoxysome
- Peroxisome
- Weibel–Palade body
|
|
| Cytoskeleton |
- Microfilaments
- Intermediate filaments
- Microtubules
- Prokaryotic cytoskeleton
- MTOCs
- Centrosome
- Centriole
- Basal body
- Spindle pole body
- Myofibril
|
|
| Endosymbionts |
- Mitochondrion
- Plastids
- Chloroplast
- Chromoplast
- Gerontoplast
- Leucoplast
- Amyloplast
- Elaioplast
- Proteinoplast
- Tannosome
|
|
| Other internal |
- RNA
- Ribosome
- Spliceosome
- Vault
- Cytoplasm
- Proteasome
|
|
| External |
- Undulipodium
- Cilium
- Flagellum
- Axoneme
- Radial spoke
- Extracellular matrix
|
|
